| Literature DB >> 35706795 |
Guiping Yang1, Sen Shen1, Jiajia Zhang1, Yan Gu1.
Abstract
Background: Psychological resilience has played an increasingly important role in the treatment of different diseases and many glioma patients will experience adverse emotional reactions after being diagnosed. However, it remains unclear whether psychological resilience is related to the adverse events and quality of life of patients with glioma.Entities:
Keywords: Psychological resilience; glioma; postoperative adverse events; quality of life (QoL); retrospective study
Year: 2022 PMID: 35706795 PMCID: PMC9189234 DOI: 10.21037/tcr-22-732
Source DB: PubMed Journal: Transl Cancer Res ISSN: 2218-676X Impact factor: 0.496
Figure 1Patient selection flow chart.
Demographic and clinical data of the included glioma patients
| Variables | Total | High resilience group | Low resilience group | P value |
|---|---|---|---|---|
| Number | 381 | 97 | 284 | |
| Gender (male) | 188 (49.3%) | 57 (58.8%) | 131 (46.1%) | 0.032 |
| Age, mean ± SD | 61.4±13.8 | 58.9±12.1 | 62.2±14.3 | 0.037 |
| BMI, mean ± SD | 23.0±5.3 | 22.8±4.8 | 23.1±5.4 | 0.620 |
| Spouse | 339 (90.0%) | 87 (89.7%) | 252 (88.7%) | 0.795 |
| Educational level (college or above) | 41 (10.8%) | 19 (19.6%) | 22 (7.7%) | 0.001 |
| Employment status (employed) | 153 (40.2%) | 34 (35.1%) | 119 (41.9%) | 0.235 |
| Duration of disease, mean ± SD (month) | 25.3±7.5 | 25.6±7.7 | 25.2±6.7 | 0.689 |
| Concomitant diseases | ||||
| Hypertension | 100 (26.2%) | 20 (50.5%) | 80 (28.2%) | 0.144 |
| Smoking | 51 (13.4%) | 10 (10.3%) | 41 (14.4%) | 0.303 |
| Diabetes | 30 (7.9%) | 6 (6.2%) | 24 (8.5%) | 0.475 |
| Chronic lung disease | 10 (2.6%) | 3 (3.1%) | 7 (2.5%) | 0.738 |
| Chronic liver dysfunction | 28 (7.3%) | 6 (6.2%) | 22 (7.7%) | 0.611 |
| Tumor position | 0.201 | |||
| Frontal lobe | 126 (33.1%) | 26 (26.8%) | 100 (35.2%) | |
| Temporal lobe | 84 (22.0%) | 24 (24.7%) | 60 (21.1%) | |
| Parietal lobe | 69 (18.1%) | 15 (15.5%) | 54 (19.0%) | |
| Multiple lobes | 70 (18.4%) | 23 (23.7%) | 47 (16.5%) | |
| Other lobes | 32 (8.4%) | 9 (9.3%) | 23 (8.1%) | |
| Tumor location | 0.932 | |||
| Left | 183 (48.0%) | 48 (49.5%) | 135 (47.5%) | |
| Right | 189 (49.6%) | 47 (48.5%) | 142 (50.0%) | |
| Both | 9 (2.4%) | 2 (2.1%) | 7 (2.5%) | |
| Extent of resection | 0.141 | |||
| Gross total resection | 285 (74.8%) | 78 (80.4%) | 207 (72.9%) | |
| Partial resection | 96 (25.2%) | 19 (19.6%) | 77 (27.1%) | |
| WHO grade | 0.413 | |||
| II | 70 (18.4%) | 14 (14.4%) | 56 (19.7%) | |
| III | 189 (49.6%) | 48 (49.5%) | 141 (49.6%) | |
| IV | 122 (32.0%) | 35 (36.1%) | 87 (30.6%) | |
| Histopathology | 0.498 | |||
| Glioblastoma | 80 (21.0%) | 21 (21.6%) | 59 (20.8%) | |
| Low-grade glioma | 211 (55.4%) | 36 (37.1%) | 124 (43.7%) | |
| High-grade glioma | 90 (23.6%) | 40 (41.2%) | 101 (35.6%) | |
| Karnofsky performance scale, mean ± SD | 79.8±11.0 | 80.7±9.9 | 79.4±13.2 | 0.416 |
BMI, body mass index; WHO, World Health Organization.
Postoperative adverse events of the included glioma patients
| Variables | Total | High resilience group | Low resilience group | P value |
|---|---|---|---|---|
| Number | 381 | 97 | 284 | |
| Neurological complications | 61 (16.0%) | 8 (8.2%) | 53 (18.7%) | 0.016 |
| Intracranial hemorrhage | 9 (2.4%) | 3 (3.1%) | 6 (2.1%) | 0.412 |
| Cerebrovascular accident | 22 (5.8%) | 5 (5.2%) | 17 (6.0%) | 0.762 |
| Postoperative ventilator use | 17 (4.5%) | 5 (5.2%) | 12 (4.2%) | 0.702 |
| Acute kidney injury | 50 (13.1%) | 9 (9.3%) | 50 (17.6%) | 0.050 |
| Septic shock | 11 (2.9%) | 3 (3.1%) | 8 (2.8%) | 0.889 |
Risk factors of neurological complications in glioma patients
| Variables | Multivariable logistic regression | |
|---|---|---|
| OR (95% CI) | P value | |
| Age | 1.042 (1.017 to 1.069) | 0.001 |
| Duration of disease | 1.050 (1.003 to 1.100) | 0.038 |
| Karnofsky performance scale | 0.956 (0.930 to 0.983) | 0.001 |
| High resilience | 0.413 (0.184 to 0.927) | 0.032 |
OR, odds ratio; CI, confidence interval.
Figure 2Scores of each item in the EORTC QLQ-C30 (A) and EORTC QLQ-BN20 (B) between the high and low resilience groups. *, P<0.05. EORTC QLQ, The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire.
Risk factors of postoperative QoL in glioma patients
| Variables | Multivariable linear regression | |
|---|---|---|
| β (95% CI) | P value | |
| Age | –0.172 (–0.282 to –0.062) | 0.002 |
| Karnofsky performance scale | 0.229 (0.113 to 0.344) | <0.001 |
| Higher educational level | 4.960 (0.800 to 9.119) | 0.020 |
| Higher tumor grade | –2.243 (–4.097 to –0.390) | 0.018 |
| High resilience | 5.102 (2.152 to 8.052) | 0.001 |
QoL, quality of life; CI, confidence interval.
Demographic and clinical data in the subgroup analysis
| Variables | Increased resilience group | Decreased resilience group | P value |
|---|---|---|---|
| Number | 26 | 35 | |
| Gender (male) | 14 (53.8%) | 15 (42.9%) | 0.395 |
| Age, mean ± SD | 60.7±12.1 | 61.9±12.1 | 0.479 |
| BMI, mean ± SD | 24.4±5.3 | 22.9±3.9 | 0.227 |
| Spouse | 23 (53.8%) | 31 (88.6%) | 0.989 |
| Educational level (college or above) | 4 (15.4%) | 4 (11.4%) | 0.651 |
| Employment status (employed) | 8 (30.8%) | 13 (37.1%) | 0.604 |
| Duration of disease , mean ± SD (month) | 24.6±8.1 | 24.2±5.8 | 0.803 |
| Concomitant diseases | |||
| Hypertension | 4 (15.4%) | 8 (22.9%) | 0.468 |
| Smoking | 2 (7.7%) | 4 (11.4%) | 0.628 |
| Diabetes | 1 (3.8%) | 1 (2.9%) | 0.830 |
| Chronic lung disease | 0 (0%) | 0 (0%) | – |
| Chronic liver dysfunction | 0 (0%) | 2 (5.7%) | 0.215 |
| Tumor position | 0.468 | ||
| Frontal lobe | 7 (26.9%) | 14 (40.0%) | |
| Temporal lobe | 7 (26.9%) | 4 (11.4%) | |
| Parietal lobe | 3 (11.5%) | 6 (17.1%) | |
| Multiple lobes | 7 (26.9%) | 7 (20.0%) | |
| Other lobes | 2 (7.7%) | 4 (11.4%) | |
| Tumor location | 0.575 | ||
| Left | 15 (57.7%) | 17 (48.6%) | |
| Right | 11 (42.3%) | 17 (48.6%) | |
| Both | 0 (0%) | 1 (2.9%) | |
| Extent of resection | 0.628 | ||
| Gross total resection | 23 (88.5%) | 30 (85.7%) | |
| Partial resection | 3 (11.5%) | 5 (14.3%) | |
| WHO grade | 0.725 | ||
| II | 2 (7.7%) | 5 (14.3%) | |
| III | 15 (57.7%) | 19 (54.3%) | |
| IV | 9 (34.6%) | 11 (31.4%) | |
| Histopathology | 0.711 | ||
| Glioblastoma | 3 (11.5%) | 4 (11.4%) | |
| Low-grade glioma | 13 (50.0%) | 14 (40.0%) | |
| High-grade glioma | 10 (38.5%) | 17 (48.6%) | |
| Karnofsky performance scale , mean ± SD | 80.9±12.8 | 80.0±13.8 | 0.582 |
BMI, body mass index; WHO, World Health Organization.
Postoperative adverse events in the subgroup analysis
| Variables | Increased resilience group | Decreased resilience group | P value |
|---|---|---|---|
| Number | 26 | 35 | |
| Neurological complications | 1 (3.8%) | 8 (22.9%) | 0.039 |
| Intracranial hemorrhage | 0 (0%) | 1 (2.9%) | 0.385 |
| Cerebrovascular accident | 1 (3.8%) | 4 (11.4%) | 0.286 |
| Postoperative ventilator use | 0 (0%) | 2 (5.7%) | 0.215 |
| Acute kidney injury | 3 (11.5%) | 7 (20.0%) | 0.301 |
| Septic shock | 0 (0%) | 2 (5.7%) | 0.215 |
Figure 3Scores of each item in the EORTC QLQ-C30 (A) and EORTC QLQ-BN20 (B) between the increased and decreased resilience groups. *, P<0.05. EORTC QLQ, The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire.